Search Within

Department of Medicine

Formats
  1. Journal Article (19593)
  2. Meeting Abstract (16038)
  3. Review (1150)
  4. Book Section (934)
  5. Editorial (610)
  6. Research Letter (314)
  7. Conference Paper (301)
  8. Guidelines (295)
  9. Correspondence (236)
  10. Miscellaneous (90)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22321)
  2. Hematologic Malignancies, Division of (13278)
  3. Center for Hematologic Malignancies (11061)
  4. GSK Faculty (10646)
  5. Survivorship Research (9330)
  6. Division of Subspecialty Medicine (7535)

More Groups

People
  1. Robert Motzer (1248)
  2. Howard Scher (1132)
  3. Sergio Giralt (1069)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (905)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1071)
  2. 2024 (2291)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3722)
  3. Annals of Oncology (1398)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (902)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6458)
  2. Elsevier Inc. (4216)
  3. American Society of Hematology (4003)
  4. American Association for Cancer Research (2896)
  5. Oxford University Press (2286)
  6. Nature Publishing Group (2111)

More Publishers

Results (39622)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • 5-year follow-up of the phase 2 optic study in patients with chronic-phase chronic myeloid leukemia: Efficacy, safety, and first end-of-treatment mutational results
    Meeting Abstract

    Cortes, J. E.; Deininger, M. W.; Apperley, J.; Arthur, C. K.; Chuah, C.; Hochhaus, A.; de Lavallade, H.; Lipton, J. H.; Lomaia, E.; McCloskey, J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Updated results from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for Janus kinase inhibitor-naive patients with myelofibrosis
    Meeting Abstract

    Mascarenhas, J. O.; Grosicki, S.; Chraniuk, D.; Abruzzese, E.; Bose, P.; Gerds, A. T.; Vannucchi, A. M.; Palandri, F.; Lee, S. E.; Gupta, V.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Patients with AML and an IDH2-R172 mutation exhibit a unique response to intensive induction chemotherapy, suggesting futility of mid-cycle bone marrow biopsy and caution when considering re-induction
    Meeting Abstract

    Yisraeli Salman, M.; Terry, A. R.; Derkach, A.; Nemirovsky, D.; Chin, K. K.; Valtis, Y. K.; Boussi, L.; Spivey, T.; Xiao, W.; Famulare, C.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Final response and survival results from a phase II trial of pembrolizumab and entinostat in relapsed/refractory Hodgkin lymphoma
    Meeting Abstract

    Stuver, R.; Vardhana, S. A.; Ganesan, N.; Boardman, A. P.; Caron, P.; Chang, T.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Pembrolizumab for front-line treatment of extranodal NK/T-cell lymphoma
    Meeting Abstract

    Moskowitz, A.; Advani, R. H.; Ganesan, N.; Chang, T.; Hancock, H.; Davey, T.; Miller, T.; Gibaldi, A.; Smith, M.; Assini, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Duvelisib in patients with relapsed/refractory peripheral T-cell lymphoma: Final results from the phase 2 PRIMO trial
    Meeting Abstract

    Mehta-Shah, N.; Zinzani, P. L.; Jacobsen, E. D.; Zain, J.; Mead, M.; Casulo, C.; Gritti, G.; Pinter-Brown, L. C.; Izutsu, K.; Bentur, O. S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Codon-specific differences in RAS mutations in AML and differential response to therapeutic agents
    Meeting Abstract

    Anandappa, A. J.; Trivedi, V.; Merlinsky, T.; Delgaudio, N.; Guzzardi, E.; Wooten, A.; Starczynowski, D.; Bowman, R. L.; Levine, R.; Miles, L. A.
    Blood (2024)

    Fulltext@MSK | Save
  • Efficacy of a novel BCL-XL degrader, DT2216, in preclinical models of post-myeloproliferative neoplasm secondary AML
    Meeting Abstract

    Wang, Z.; Skwarska, A.; Poigailwar, G.; Chaudhry, S.; Rodriguez-Meira, A.; Sui, P.; Olivier, E.; Jia, Y.; Ramage, C. L.; Zheng, G.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • The LMO2-LDB1-TAL1 complex regulates transcription networks in AML relapse
    Meeting Abstract

    Dunham, N.; Wang, Z.; Neelamraju, Y.; Guo, Y.; Hardwick, J.; Maier, B.; Meydan, C.; Gandara, J. A.; Lee, T.; Prajapati, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • TET2 and TP53 mutations cooperate in leukemia development and modulate the response to inflammation
    Meeting Abstract

    Vela, P. S.; Kelly, B.; Brady, C.; Foox, J.; Glass, J.; Levine, R. L.; Shih, A. L.
    Blood (2024)

    Fulltext@MSK | Save